- Trial phase
- Approved
- Time to market
- Already approved and on the market, FDA original approval granted 2026-05-27 (BLA 761460).
- Why 3/10
- No dated binary is scheduled for Decnupaz in the next ~12 months, the defining catalyst (FDA approval) already passed on 2026-05-27, and as an approved niche orphan-drug launch inside a mega-cap pipeline with no pending PDUFA/readout, near-term share-price impact is small.
Watch AbbVie earnings calls for first commercial-update commentary on Decnupaz (launch ramp, pricing, and any label-expansion trial starts), but treat this as a rounding-error program for a ~$250B company rather than a stock-driving catalyst.
Price Chart
Executive Summary
Decnupaz (generic: pivekimab sunirine) is AbbVie's intravenously administered, new-molecular-entity cancer drug that the FDA approved on 2026-05-27 under priority review with orphan-drug designation (BLA 761460, AbbVie Inc. as sponsor). The approval is a genuine regulatory win but sits inside AbbVie's enormous diversified portfolio, so it is immaterial to the stock's valuation.
How It Works
Decnupaz is an intravenously infused prescription cancer medicine, a brand-new molecular entity (Type 1 NME) approved with orphan-drug (rare-disease) status.
Trial Status
FDA granted an original approval (Type 1 New Molecular Entity) on 2026-05-27 under PRIORITY review with orphan-drug designation, per the FDA action record (application BLA761460, sponsor AbbVie Inc.). The record shows a prescription, single-dose 2 mg intravenous vial; no pending regulatory decision or next readout was identified in local data.
The Two-Sided Case
Upcoming Catalysts
- None confirmed for Decnupaz: no pending PDUFA, advisory-committee, or pivotal-readout date identified in local data.
- First commercial/launch commentary on Decnupaz in AbbVie quarterly earnings (next 10-Q/earnings call), watch for revenue disclosure and label-expansion trial starts.
- Any future sNDA filing for additional indications would be the next potential hard catalyst, but none is scheduled per available data.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report